Please try another search
ZS Pharma, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver, and metabolic diseases. The company’s proprietary zirconium silicate technology creates ion traps that could reduce toxic levels of specific electrolytes without disturbing the balance of other electrolytes. It is developing ZS-9, insoluble non-absorbed zirconium silicate that is in Phase III development for the treatment of hyperkalemia. The company was founded in 2008 and is headquartered in San Mateo, California. As of December 16, 2015, ZS Pharma, Inc. operates as a subsidiary of AstraZeneca PLC.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review